AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03150524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil ER
Description: Participants will be administered long acting verapamil every 12 hours.
Study NCT02671318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug conversion to sirolimus
Description: Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
Study NCT02671318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of the current regimen
Description: Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
Study NCT03219255 — intervention group
Intervention type: DRUG
Intervention: RELVAR 100 ELLIPTA
Description: RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
Study NCT02450123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Study NCT01178281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 0.5 mg
Description: Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
Study NCT01178281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
Study NCT01178281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 0.5 mg capsule taken by mouth once daily.
Study NCT02895698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry cupping
Description: Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
Study NCT04401761 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (BAY59-7939, Xarelto)
Description: 2.5 mg twice daily
Study NCT02895698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stretching exercises
Description: * The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~* Standing self-stretching of the calf muscles.~* Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~* All stretches were done six times and the duration of each stretch is 30 seconds.
Study NCT03220659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-point pacing
Description: Pacing from more than one pole from the left ventricular lead
Study NCT03220659 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard settings
Description: Normal bipolar LV pacing
Study NCT04225637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrew-Supported Maxillary Expander- Slow activation
Description: A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.
Study NCT04225637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrew-Supported Maxillary Expander- Rapid activation
Description: A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
Study NCT01265589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: surfactant
Description: Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
Study NCT04401761 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic acid
Description: 75 - 100 mg once daily at the discretion of the investigator
Study NCT04482075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: segmental stability training
Description: SEGMENTAL STABILISATION TRAINING (SST): This part of the therapy shall involve Isometric co-contraction of Lumbar Transversus abdominis and Lumbar Multifidus. The patient shall perform 10 repetitions of abdominal drawing-in manoeuvre with 30-40% Maximal Voluntary Contraction (MVC) with a 10-second hold in specific prescribed positions.
Study NCT00831298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of sleep disturbance
Description: Behavioral Questionnaire Sleep Recordings Genetic analysis
Study NCT01265589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surfactant+vitamin A
Description: Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
Study NCT01550835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)
Description: Standard of care use of an embolic protection device
Study NCT01550835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)
Description: Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
Study NCT01254890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
Study NCT01254890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
Study NCT03457272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New risk assessment
Description: Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles.
Study NCT04140825 — intervention group
Intervention type: DEVICE
Intervention: Resmon PRO FULL
Description: Measurement of lung impedance by the Forced Oscillation Technique
Study NCT00295438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Based Tele-Echography (TER)
Description: Robot-Based Tele-Echography, ultrasound performed by the radiologist
Study NCT00295438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-Based Tele-Echography (TER)
Description: Robot-Based Tele-Echography, ultrasound performed by the radiologist
Study NCT03784625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 1)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 800 MBq/m²
Study NCT03784625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 2)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²
Study NCT03784625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 3)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²
Study NCT03784625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 4)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²
Study NCT00295438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound method FAST
Description: FAST,ultrasound performed by the emergency doctor
Study NCT00295438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound method FAST
Description: FAST,ultrasound performed by the emergency doctor
Study NCT01688960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 1
Study NCT01688960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 2
Study NCT01688960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 3
Study NCT01688960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept)
Description: Dose level 1
Study NCT01688960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept)
Description: Dose level 2
Study NCT01809041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study NCT01809041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT01809041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Study NCT01809041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Study NCT01759615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Enteral feeding
Description: Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
Study NCT01759615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late enteral feeding
Description: Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
Study NCT03075956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg E4 single-dose
Description: A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
Study NCT03075956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4 single-dose
Description: A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
Study NCT03075956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg E4 single-dose
Description: A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
Study NCT03075956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4 multiple-dose
Description: 15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
Study NCT02386917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Weight loss surgery
Study NCT02386917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet
Description: Non-surgical weight loss procedure
Study NCT01017978 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Scan of soft tissue tumor
Description: MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
Study NCT04031430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
Study NCT04031430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
Study NCT04031430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication
Description: Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
Study NCT04031430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV profiling before and after the start/switch of antihypertensive medication
Description: CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
Study NCT04282564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-OP treatment
Description: The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke
Study NCT04584359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA
Description: High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
Study NCT04584359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global osteopathic protocol
Description: Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
Study NCT04584359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
Study NCT03840200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally.
Study NCT03840200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered orally.
Study NCT01357447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dornase alfa
Description: Dose: 2.5 mg solution BID via nebuliser for 2 weeks
Study NCT01357447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
Study NCT01357447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
Study NCT01495234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP device
Description: The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
Study NCT03535077 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Test
Description: Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
Study NCT04428983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hericium erinaceus mycelium
Description: Hericium erinaceus capsules 3 tables per day for 24 months
Study NCT04428983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hericium erinaceus mycelium
Description: Hericium erinaceus capsules 3 tables per day for 24 months
Study NCT02303002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Intramuscular injection (IM)
Study NCT02303002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator botulinum toxin
Description: IM injection
Study NCT02303002 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: IM injection
Study NCT02646189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2139-Ca
Description: REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
Study NCT02646189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zadaxin
Description: Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
Study NCT02646189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
Study NCT00282828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT00282828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Study NCT06625359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa in conditioning before transplantation
Description: For patients with ECOG PS 0 or 1 For patients with ECOG PS 0 or 1 and age \&lt; 60 years old, conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9. Beginning on day -9 and through day -7, each patient was treated with thiotepa (200mg/m m2 IV per day). On days -6 to -4, patients received bulsulfan (2.7mg/kg IV over 3 hours per day every). Bulsulfan-related seizure prophylaxis was given with levetriacetam (1500mg loading on day -6, 500mg twice daily on days -5 to -3). On days -3 and -2, cyclophosphamide (60mg/kg IV per day) was given given.~Patients with ECOG PS 2 or age ≥ 60 years old received bulsulfan (3.2mg/kg IV over 3 hours per day for 2 days) resulting in 8 days regimen.
Study NCT00282828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00282828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Study NCT03045055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning.
Description: The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
Study NCT03045055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment.
Description: Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.